<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00318188</url>
  </required_header>
  <id_info>
    <org_study_id>AOM04023</org_study_id>
    <nct_id>NCT00318188</nct_id>
  </id_info>
  <brief_title>Effects of a Personalized Standardized Rehabilitation Program in Systemic Sclerosis</brief_title>
  <acronym>SCLEREDUC</acronym>
  <official_title>Effects of a Personalized Standardized Rehabilitation Program on the Quality of Life of Patients With Systemic Sclerosis Patients : a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Systemic sclerosis (SSc) is a connective-tissue disease characterized by excessive collagen
      deposition, vascular hyper-reactivity and obliterative microvascular phenomena leading to
      disability, handicap, and worsening of quality of life. Pharmacological treatments are mainly
      used for vascular involvement. To date, no pharmacological treatment have been shown to be
      effective for the fibrosis leading to skin, tendon, and joint disability. Our hypothesis is
      that rehabilitation could be an interesting non pharmacological treatment in order to
      decrease the handicap of SSc patients. Our objective is to evaluate the effect of a
      personalized standardized rehabilitation program on the quality of life of SSc patients in a
      multicentric randomized controlled trial. This trial will compare a personalized standardized
      rehabilitation program to the usual non pharmacological treatment. The primary outcome
      measure will be the HAQ DI (Health Assessment Questionnaire Disability Index). A Zelen design
      will be used for this study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2005</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HAQ DI:Health Assessment questionnaire disability index</measure>
    <time_frame>at 12 months</time_frame>
    <description>Health Assessment questionnaire disability index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mac Tar (Mc Master Toronto Arthritis questionnaire)</measure>
    <time_frame>at 12 months</time_frame>
    <description>Mc Master Toronto Arthritis questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>S-HAQ ( scleroderma-modified health assessment questionnaire)</measure>
    <time_frame>at 12 months</time_frame>
    <description>Scleroderma-modified health assessment questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF 36</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kapandji modified index</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rodnan score</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hand Cochin Function Scale</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mouth opening</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced expiratory volume (FEV)</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction of clinical condition</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Systemic Scleroderma</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients in this group will do a personalized standardized rehabilitation program on the quality of life.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Habitual care</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>standardized reeducation and readaptation program</intervention_name>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women aged from 18 years or more, with diagnostic of SSc considering the ACR
             and/or Leroy and Medsger's criteria.

          -  HAQ greater than or equal to 0.5

          -  A perception of limitation of mouth opening and/or at least one limitation in range of
             motion due to illness

          -  Good understanding of the French language

        Exclusion Criteria :

          -  Associated chronic handicap diseases (stroke, multiple sclerosis, amyotrophic lateral
             sclerosis, Parkinson's disease, amputated ....)

          -  Any underlying disease that may be incompatible with the management, discovery at the
             inclusion visit

          -  Cognitive problems making it impossible to assess the primary outcome measure

          -  Patients with a standardized rehabilitation program within 6 months prior to inclusion

          -  Impairment of comprehension or expression of the French language

          -  Patients participating in another clinical trial or participated in another clinical
             trial in the previous 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Serge POIRAUDEAU, MD-PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Reeducation and readaptation Department</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Rannou F, Boutron I, Mouthon L, Sanchez K, Tiffreau V, Hachulla E, Thoumie P, Cabane J, Chatelus E, Sibilia J, Roren A, Berezne A, Baron G, Porcher R, Guillevin L, Ravaud P, Poiraudeau S. Personalized Physical Therapy Versus Usual Care for Patients With Systemic Sclerosis: A Randomized Controlled Trial. Arthritis Care Res (Hoboken). 2017 Jul;69(7):1050-1059. doi: 10.1002/acr.23098. Epub 2017 Jun 7.</citation>
    <PMID>27696703</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2006</study_first_submitted>
  <study_first_submitted_qc>April 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2006</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>scleroderma</keyword>
  <keyword>HAQ</keyword>
  <keyword>Intensive care reeducation, readaptation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

